Drug Profile
Research programme: diabetic nephropathies therapy - NephroGenex
Alternative Names: BST 4946; BST 4996; BST 4997; BST-605Latest Information Update: 12 May 2006
Price :
$50
*
At a glance
- Originator BioStratum
- Developer NephroGenex
- Class Imidazoles; Piperazines; Pyridines
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic nephropathies
Most Recent Events
- 12 May 2006 NephroGenex licenses second generation AGE compounds, including BST 605, from BioStratum
- 17 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
- 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)